Combination therapy for unresectable peritoneal mesothelioma
Part of Cancer clinical trials.
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with peritoneal mesothelioma (a cancer in the lining of your abdomen) that cannot be removed by surgery.
- You are 18 years or older.
- You can care for yourself and are up and about more than half the day (ECOG score 0-1).
- Your kidney and liver function are good, and your blood counts are within safe ranges.
- You do not have an active autoimmune disease or uncontrolled bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a test on your tumor tissue to find which chemotherapy drugs work best for you, after standard surgery and heated chemotherapy. It aims to make your treatment more effective by choosing drugs that match your cancer.
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
This trial tests a combination of four medicines (two newer immune-boosting drugs, a blood vessel-blocking drug, and chemotherapy) to treat advanced mesothelioma—a serious lung cancer caused by asbestos exposure. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether more chemotherapy after surgery can help people with a specific type of abdominal cancer (malignant peritoneal mesothelioma). It is for those who have had all visible tumor removed and have not had chemotherapy before.
This study tests whether adding immunotherapy to standard chemotherapy helps people with peritoneal mesothelioma, a cancer in the lining of the abdomen. You may receive chemotherapy alone or with immunotherapy, and the goal is to improve cancer control.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
Hear when a new Malignant Peritoneal Mesothelioma, Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.